Overview: Post-Secretin Gastrin Levels TestIntroduction: The Post-Secretin Gastrin Levels Test measures gastrin levels after secretin stimulation to diagnose Zollinger-Ellison syndrome, causing stomach ulcers or pain, helping guide treatment. Affecting 1 in 1,000,000 people, Zollinger-Ellison syndrome poses diagnostic challenges due to rare presentation. Following 2023 American Gastroenterological Association (AGA) guidelines, it uses immunoassay for high accuracy, supporting endocrinology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in gastroenterology.
Other Names: Post-Secretin Gastrin Test, Zollinger-Ellison Assay.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic reliability.
Historical Milestone: Post-secretin gastrin testing began in the 1970s with research by Isenberg, who linked it to Zollinger-Ellison. Immunoassay advancements in the 1980s by Roche improved detection, surpassing earlier radioimmunoassay methods.
Purpose: Measures gastrin levels to diagnose Zollinger-Ellison syndrome, guides surgery or medication, and evaluates patients with ulcers, aiming to manage symptoms.
Test Parameters: Gastrin levels
Pretest Condition: Secretin injection required. Collect serum or plasma. Report history of ulcers.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document stomach ulcers or abdominal pain. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., cancer), and sample collection risks.
Procedural Considerations: Uses immunoassay to measure levels, requiring labs with analyzers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or improper secretin dose can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated levels suggest Zollinger-Ellison syndrome, guiding therapy. Early treatment might prevent complications, while untreated cases lead to cancer. Normal levels may require other tests.
Specialist Consultation: Consult a gastroenterologist or endocrinologist for interpretation.
Additional Supporting Tests: Endoscopy, fasting gastrin, or imaging to confirm diagnosis.
Test Limitations: Specific to secretin response; correlation with clinical status needed. False negatives possible with early disease.
References: AGA Guidelines, 2023; Gastroenterology, Isenberg JI, 2022.
